Orexo signs commercial partnership agreement with Sober Grid allowing community users access to clinically proven digital therapies vorvida® and deprexis®
Orexo AB (OTCQX: ORXOY) has partnered with Sober Grid, enhancing access to its digital therapies vorvida® and deprexis® for over 300,000 users. The partnership aims to provide effective support for problematic alcohol use and depression. Available initially through Sober Grid's peer coaches in August 2021, the therapies will later be accessible to all users via the app, demonstrating Orexo's commitment to mental health support through innovative digital solutions.
- Partnership with Sober Grid expands access to digital therapies vorvida® and deprexis®.
- Targeting a large user base of over 300,000 individuals in addiction recovery.
- Digital therapies utilize artificial intelligence for personalized user support.
- None.
UPPSALA, Sweden, July 12, 2021 /PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) and Sober Grid, the largest social media network for those in addiction recovery, today announced that Sober Grid's more than 300,000 users will gain access to Orexo's clinically proven digital therapies vorvida®, for problematic alcohol use, and deprexis® for depression, through their new commercial partnership.
The Sober Grid community will be able to take advantage of vorvida® and deprexis®, digital therapies that help reduce problematic drinking patterns in adults and manage symptoms of depression, respectively. Orexo's digital therapies will first be available through Sober Grid's network of peer coaches in August 2021. Later in the year, vorvida® and deprexis® will be available to any user on the app.
Nikolaj Sørensen, President and CEO, Orexo, said: "This exciting partnership gives us a fantastic opportunity to reach out with vorvida® and deprexis® to a large group of people struggling with mental illness and are in need of support. The agreement with Sober Grid is the result of persistent work within our DTx team that is working tirelessly to encourage the market to start gaining momentum as well as to develop exciting commercial concept for our digital therapies."
Through an online platform, Orexo's digital therapeutics successfully provide cognitive behavioural therapy and other effective psychotherapeutic techniques across all devices, anytime, anywhere. The programs are supported by artificial intelligence, which individualizes and tailors content delivery based on the user's progress and specific needs.
"Sober Grid has given us opportunity to create a space where people can turn to for inspiration, support, and understanding, no matter their situation," said Beau Mann, Chief Executive Officer and Founder, Sober Grid. "Through our new partnership with Orexo, we're able to take that one step further by equipping our community members with clinically proven digital therapy–24 hours a day, 7 days a week."
For further information, please contact:
Orexo AB (publ.)
Nikolaj Sørensen, President and CEO
Tel: +46 (0)18 780 88 00
Email: ir@orexo.com
Sober Grid
Beau Mann, CEO and Founder
Tel: +1 857 206 0569
Email: beau@sobergrid.com
Lena Wange, IR & Communications Director
Tel: +46 (0)18 780 88 00
Email: ir@orexo.com
About Sober Grid
Sober Grid is a free iOS/Android app that connects you with other people in or seeking recovery from Substance Use Disorders. Members are instantly connected to a global community in their neighbourhoods and around the globe. Members can build strong support networks and inspire others. Sober Grid, Founded by CEO Beau Mann, started because he was looking for a supportive community that could be accessed anytime anywhere. Today it is a platform full of evidence-based tools to help anyone get instant addiction support. Sober Grid now offers affordable 24/7 Certified Peer Coaches to assist individuals in their recovery. Its peer coaches are trained and certified to help you along your recovery journey. For more information, visit http://www.sobergrid.com
About Orexo
Orexo develops improved pharmaceuticals and digital therapies addressing unmet needs within the growing space of substance use disorders and mental illness. The products are commercialized by Orexo in the US or via partners worldwide. The main market today is the US market for buprenorphine/naloxone products, where Orexo commercializes its lead product, ZUBSOLV®, for treatment of opioid use disorder. Total net sales for Orexo in 2020 amounted to SEK 664 million and the number of employees was 138. Orexo is listed on the Nasdaq Stockholm Mid Cap (ORX) and is available as ADRs on OTCQX (ORXOY) in the US. The company is headquartered in Uppsala, Sweden, where research and development activities are performed.
For more information about Orexo please visit www.orexo.com. You can also follow Orexo on Twitter, @orexoabpubl, LinkedIn, and YouTube.
The information was submitted for publication at 8 a.m. CET, on July 12, 2021.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Orexo Group_PR_Orexo signs commercial partnership agreement with Sober Grid incl access to vorvida and deprexis_Published July 12 2021 |
View original content:SOURCE Orexo
FAQ
What is the significance of Orexo's partnership with Sober Grid?
When will Orexo's therapies be available on Sober Grid?
What are the main benefits of Orexo's digital therapies?
What are the expected outcomes from Orexo's partnership with Sober Grid?
What is the ticker symbol for Orexo on OTC markets?
